Janux Therapeutics (JANX) Cash from Financing Activities (2020 - 2026)
Janux Therapeutics (JANX) posted quarterly Cash from Financing Activities of $3.5 million for Q1 2026, up 539.89% year-over-year from $554000.0 in Q1 2025, and up 20.41% quarter-over-quarter from $2.9 million in Q4 2025.
Janux Therapeutics (JANX) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Janux Therapeutics (JANX) has reported Cash from Financing Activities for 7 consecutive years, with $3.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 539.89% year-over-year to $3.5 million; the TTM figure through Mar 2026 stood at $7.9 million (down 97.97% YoY), while the FY2025 annual figure was $4.9 million, down 99.31% from the prior year.
- Cash from Financing Activities rose to $3.5 million in Q1 2026 per JANX's latest filing, from $2.9 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $386.6 million in Q4 2024 and bottomed at $1000.0 in Q1 2022.
- Historically, Cash from Financing Activities has averaged $48.9 million across 5 years, with a median of $1.3 million in 2023.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities slumped 100.0% — and 2023, when it soared 157900.0%.
- Janux Therapeutics' Cash from Financing Activities stood at $191000.0 in 2022, then soared by 335.08% to $831000.0 in 2023, then surged by 46428.28% to $386.6 million in 2024, then tumbled by 99.24% to $2.9 million in 2025, then rose by 20.41% to $3.5 million in 2026.
- Business Quant data shows JANX's Cash from Financing Activities at $3.5 million in Q1 2026, $2.9 million in Q4 2025, and $493000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Janux Therapeutics | 984.58 Mn | 984.58 Mn | - | 2.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.24 Mn |
| Jun 30, 2026 | 2.24 Mn |
| Mar 31, 2026 | 3.55 Mn |
| Mar 31, 2026 | 3.55 Mn |
| Dec 31, 2025 | 2.94 Mn |
| Dec 31, 2025 | 2.94 Mn |
| Sep 30, 2025 | 493,000.00 |
| Sep 30, 2025 | 493,000.00 |
| Jun 30, 2025 | 954,000.00 |
| Jun 30, 2025 | 954,000.00 |
| Mar 31, 2025 | 554,000.00 |
| Mar 31, 2025 | 554,000.00 |
| Dec 31, 2024 | 386.65 Mn |
| Dec 31, 2024 | 386.65 Mn |
| Sep 30, 2024 | 1.65 Mn |
| Sep 30, 2024 | 1.65 Mn |
| Jun 30, 2024 | 2.77 Mn |
| Jun 30, 2024 | 2.77 Mn |
| Mar 31, 2024 | 322.17 Mn |
| Mar 31, 2024 | 322.17 Mn |